RxDoctor Payments Data

Kenneth Adler, MD

Psychiatry · Sylvania, OHNPI 1619072659

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 15 payments — averaging $102.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$488
  • Braeburn Inc.$232
  • Johnson & Johnson$212
  • Indivior Inc.$125
  • E.r. Squibb & Sons, L.L.C.$115
  • Alkermes, Inc.$112
  • plus $253 from 3 others

What the payments were for

  • Food & beverage$1,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,537 in reported general payments places this provider in the 75th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$55,378
Medicare patients
91
Services billed
470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl262$40,883
SuboxoneBuprenorphine Hcl/Naloxone Hcl41$23,835
Lurasidone Hcl42$16,403
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine91$4,164
Duloxetine Hcl164$3,315
Aripiprazole25$2,236
Trazodone Hcl204$2,116
Quetiapine Fumarate126$2,101
Bupropion XlBupropion Hcl113$2,005
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine27$1,694
Ondansetron OdtOndansetron11$1,524
Olanzapine72$1,180
Oxcarbazepine38$1,137
Doxepin Hcl13$1,097
Mirtazapine74$965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$125$23,83541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Sylvania

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →